Multiple pharmacological therapies, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and matrix metalloproteinase inhibitors, showed promise in AAA preclinical models but have not been effective in reducing aneurysm growth or rupture and are not recommended for treating AAA.2, 3, 4, 5, 6. The gene discussed is ACE; the disease is triple-A syndrome.